Eva Diz-Ferreira MD , Pablo Díaz-Vidal MD , Uxía Fernández-Vázquez MD , Cristina Gil-Casado MD , Pedro Luna-Rojas MD , José Carlos Diz MD, PhD
{"title":"增强术后恢复(ERAS)计划对心脏手术患者围手术期预后的影响:系统回顾和荟萃分析。","authors":"Eva Diz-Ferreira MD , Pablo Díaz-Vidal MD , Uxía Fernández-Vázquez MD , Cristina Gil-Casado MD , Pedro Luna-Rojas MD , José Carlos Diz MD, PhD","doi":"10.1053/j.jvca.2025.01.036","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Enhanced recovery after surgery (ERAS) programs emerged as a strategy to reduce perioperative morbidity; however, there is currently limited evidence of their clinical efficacy. The objective of this study was to assess the impact of ERAS programs in cardiac surgery on hospital length of stay, mortality, atrial fibrillation, and quality of life.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement, encompassing studies on ERAS programs in adult patients undergoing elective cardiac surgery. The effect size and 95% confidence interval (CI) were estimated with a random-effects model. The protocol was preregistered on Open Science Framework.</div></div><div><h3>Results</h3><div>Eighteen studies (published between 2016 and 2023) comprising 4,469 patients were included in the analysis, of which only one was a randomized controlled trial. The implementation of ERAS was associated with a reduction in hospital stay of 1.24 days (95% CI: –1.67, –0.82, p < 0.001, I<sup>2</sup> = 83%). No differences were observed between the groups in mortality (odds ratio: 0.65, 95% CI: 0.28, 1.48, p = 0.3, I<sup>2</sup> = 0%), nor in the incidence of atrial fibrillation (odds ratio: 0.77, 95% CI: 0.57, 1.03, p = 0.08, I<sup>2</sup> = 17%). A meta-analysis of quality of life was not feasible due to a lack of sufficient data.</div></div><div><h3>Conclusions</h3><div>Although ERAS programs were associated with a reduction in hospital stay and no differences in mortality or atrial fibrillation, the quality of the evidence was very low. To recommend the implementation of ERAS programs in cardiac surgery, it is necessary to have randomized studies providing evidence of its efficacy, and studies including quality of life and other patient-centered recovery criteria outcomes.</div></div>","PeriodicalId":15176,"journal":{"name":"Journal of cardiothoracic and vascular anesthesia","volume":"39 5","pages":"Pages 1325-1334"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Enhanced Recovery After Surgery (ERAS) Programs on Perioperative Outcomes in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis\",\"authors\":\"Eva Diz-Ferreira MD , Pablo Díaz-Vidal MD , Uxía Fernández-Vázquez MD , Cristina Gil-Casado MD , Pedro Luna-Rojas MD , José Carlos Diz MD, PhD\",\"doi\":\"10.1053/j.jvca.2025.01.036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Enhanced recovery after surgery (ERAS) programs emerged as a strategy to reduce perioperative morbidity; however, there is currently limited evidence of their clinical efficacy. The objective of this study was to assess the impact of ERAS programs in cardiac surgery on hospital length of stay, mortality, atrial fibrillation, and quality of life.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement, encompassing studies on ERAS programs in adult patients undergoing elective cardiac surgery. The effect size and 95% confidence interval (CI) were estimated with a random-effects model. The protocol was preregistered on Open Science Framework.</div></div><div><h3>Results</h3><div>Eighteen studies (published between 2016 and 2023) comprising 4,469 patients were included in the analysis, of which only one was a randomized controlled trial. The implementation of ERAS was associated with a reduction in hospital stay of 1.24 days (95% CI: –1.67, –0.82, p < 0.001, I<sup>2</sup> = 83%). No differences were observed between the groups in mortality (odds ratio: 0.65, 95% CI: 0.28, 1.48, p = 0.3, I<sup>2</sup> = 0%), nor in the incidence of atrial fibrillation (odds ratio: 0.77, 95% CI: 0.57, 1.03, p = 0.08, I<sup>2</sup> = 17%). A meta-analysis of quality of life was not feasible due to a lack of sufficient data.</div></div><div><h3>Conclusions</h3><div>Although ERAS programs were associated with a reduction in hospital stay and no differences in mortality or atrial fibrillation, the quality of the evidence was very low. To recommend the implementation of ERAS programs in cardiac surgery, it is necessary to have randomized studies providing evidence of its efficacy, and studies including quality of life and other patient-centered recovery criteria outcomes.</div></div>\",\"PeriodicalId\":15176,\"journal\":{\"name\":\"Journal of cardiothoracic and vascular anesthesia\",\"volume\":\"39 5\",\"pages\":\"Pages 1325-1334\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cardiothoracic and vascular anesthesia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1053077025000989\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cardiothoracic and vascular anesthesia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053077025000989","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:增强术后恢复(ERAS)计划成为降低围手术期发病率的策略;然而,目前关于其临床疗效的证据有限。本研究的目的是评估心脏外科ERAS项目对住院时间、死亡率、房颤和生活质量的影响。方法:根据系统评价和荟萃分析声明的首选报告项目进行系统评价和荟萃分析,包括选择性心脏手术成人患者ERAS项目的研究。采用随机效应模型估计效应大小和95%置信区间(CI)。该协议已在开放科学框架上预注册。结果:18项研究(发表于2016 - 2023年)纳入分析,共4469例患者,其中只有1项为随机对照试验。ERAS的实施与住院时间减少1.24天相关(95% CI: -1.67, -0.82, p < 0.001, I2 = 83%)。两组间在死亡率(优势比:0.65,95% CI: 0.28, 1.48, p = 0.3, I2 = 0%)和房颤发生率(优势比:0.77,95% CI: 0.57, 1.03, p = 0.08, I2 = 17%)方面均无差异。由于缺乏足够的数据,生活质量的荟萃分析是不可行的。结论:尽管ERAS项目与住院时间的减少有关,死亡率和房颤方面没有差异,但证据的质量很低。为了推荐在心脏手术中实施ERAS计划,有必要进行随机研究,以提供其有效性的证据,并研究包括生活质量和其他以患者为中心的恢复标准结果。
Effect of Enhanced Recovery After Surgery (ERAS) Programs on Perioperative Outcomes in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis
Background
Enhanced recovery after surgery (ERAS) programs emerged as a strategy to reduce perioperative morbidity; however, there is currently limited evidence of their clinical efficacy. The objective of this study was to assess the impact of ERAS programs in cardiac surgery on hospital length of stay, mortality, atrial fibrillation, and quality of life.
Methods
A systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement, encompassing studies on ERAS programs in adult patients undergoing elective cardiac surgery. The effect size and 95% confidence interval (CI) were estimated with a random-effects model. The protocol was preregistered on Open Science Framework.
Results
Eighteen studies (published between 2016 and 2023) comprising 4,469 patients were included in the analysis, of which only one was a randomized controlled trial. The implementation of ERAS was associated with a reduction in hospital stay of 1.24 days (95% CI: –1.67, –0.82, p < 0.001, I2 = 83%). No differences were observed between the groups in mortality (odds ratio: 0.65, 95% CI: 0.28, 1.48, p = 0.3, I2 = 0%), nor in the incidence of atrial fibrillation (odds ratio: 0.77, 95% CI: 0.57, 1.03, p = 0.08, I2 = 17%). A meta-analysis of quality of life was not feasible due to a lack of sufficient data.
Conclusions
Although ERAS programs were associated with a reduction in hospital stay and no differences in mortality or atrial fibrillation, the quality of the evidence was very low. To recommend the implementation of ERAS programs in cardiac surgery, it is necessary to have randomized studies providing evidence of its efficacy, and studies including quality of life and other patient-centered recovery criteria outcomes.
期刊介绍:
The Journal of Cardiothoracic and Vascular Anesthesia is primarily aimed at anesthesiologists who deal with patients undergoing cardiac, thoracic or vascular surgical procedures. JCVA features a multidisciplinary approach, with contributions from cardiac, vascular and thoracic surgeons, cardiologists, and other related specialists. Emphasis is placed on rapid publication of clinically relevant material.